



Série Conferências IB Unicamp 2007

O Instituto de Biologia da Unicamp convida para
a conferência do **Dr. Gerhard Zenke**

Discovery of a novel T cell activation inhibitor as an immunosuppressive drug

Data: 13 de agosto de 2007 (segunda-feira)

Horário: 15 Horas

Local: Sala da Congregação IB/Unicamp

Dr. Gerhard Zenke: Unit Head / Director, Novartis Leading Scientist, Novartis Institutes for BioMedical Research, Autoimmunity and Transplantation Disease Area, Transplantation Research.

Research Interests: Identification and development of novel immunosuppressants, development of new strategies based on the current knowledge of molecular and cellular mechanisms, the mechanism of action of presently known immunosuppressants and the processes involved in transplant rejection and autoimmunity.

Fields of experience: - Identification of targets for improved T and B cell immunosuppressants, - Development of screening assays (cellular, reporter gene assays, protein-protein binding assays, enzymatic assays) for high throughput screening, - Characterization of compounds using a panel of in vitro immunological assays (including selectivity and cytotoxicity assays, signal transduction pathway analysis), - Application of state-of-the-art technologies and development of novel methods for in vitro assays, - Investigation of the mechanism of action of immunosuppressive compounds, - Identification, evaluation and licensing-in of promising immunosuppressants, - Development of novel immunosuppressants, preparation of phase-transition documents, - Generation of monoclonal and polyclonal antibodies.

Publications: 52 (JBC, Transplantation, J. Immunology and others journals).

Patents: 10.